Cargando…

Efficacy of Body Weight Reduction on the SGLT2 Inhibitor in People with Type 2 Diabetes Mellitus

BACKGROUND: Dapagliflozin, a sodium-glucose cotransporter-2 inhibitor, reduces hyperglycemia and body weight by inhibiting renal glucose reabsorption. However, only a few studies have demonstrated efficacy of dapagliflozin for type 2 diabetic patients in Korea. We evaluated the efficacy and safety o...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cho, Hyun A, Jung, Young Lee, Lee, Yong Hoon, Lee, Yu Chang, Lee, Jung Eun, Lee, Sol Jae, Jeong, Su Jin, Kim, Chong Hwa
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Korean Society for the Study of Obesity 2017
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6484898/ https://www.ncbi.nlm.nih.gov/pubmed/31089504 http://dx.doi.org/10.7570/jomes.2017.26.2.107

Ejemplares similares

Effects of High-Dose α-Lipoic Acid on Heart Rate Variability of Type 2 Diabetes Mellitus Patients with Cardiac Autonomic Neuropathy in Korea
por: Lee, Sol Jae, et al.
Publicado: (2017)

Role of DPP-4 and SGLT2 Inhibitors Connected to Alzheimer Disease in Type 2 Diabetes Mellitus
por: Sim, A Young, et al.
Publicado: (2021)

A Novel Therapeutic Agent for Type 2 Diabetes Mellitus: SGLT2 Inhibitor
por: Jung, Chang Hee, et al.
Publicado: (2014)

Protocol of BEYOND trial: Clinical BEnefit of sodium-glucose cotransporter-2 (SGLT-2) inhibitors in rhYthm cONtrol of atrial fibrillation in patients with diabetes mellitus
por: Lee, Kyuhyun, et al.
Publicado: (2023)

Glycemic Variability Impacted by SGLT2 Inhibitors and GLP 1 Agonists in Patients with Diabetes Mellitus: A Systematic Review and Meta-Analysis
por: Lee, Heeyoung, et al.
Publicado: (2021)

SAT660 Predictors Of Achieving Body Weight Reduction ≥20% With Tirzepatide In People With Overweight Or Obesity In SURMOUNT-1
por: Srinath, Reshmi, et al.
Publicado: (2023)

Sodium/glucose Co-Transporter 2 Inhibitor, Empagliflozin, Alleviated Transient Expression of SGLT2 after Myocardial Infarction
por: Lee, Soo Yong, et al.
Publicado: (2020)

Combining SGLT2 Inhibition With a Thiazolidinedione Additively Attenuate the Very Early Phase of Diabetic Nephropathy Progression in Type 2 Diabetes Mellitus
por: Han, Eugene, et al.
Publicado: (2018)

Barriers to initiating SGLT2 inhibitors in diabetic kidney disease: a real-world study
por: Jeong, Su Jin, et al.
Publicado: (2021)

SGLT2 inhibition modulates NLRP3 inflammasome activity via ketones and insulin in diabetes with cardiovascular disease
por: Kim, So Ra, et al.
Publicado: (2020)

Effect of Sodium-Glucose Cotransporter-2 Inhibitors versus Dipeptidyl Peptidase 4 Inhibitors on Cardiovascular Function in Patients with Type 2 Diabetes Mellitus and Coronary Artery Disease
por: Lee, Sook Jung, et al.
Publicado: (2019)

Dapagliflozin, SGLT2 Inhibitor, Attenuates Renal Ischemia-Reperfusion Injury
por: Chang, Yoon-Kyung, et al.
Publicado: (2016)

Response: Effects of High-Dose α-Lipoic Acid on Heart Rate Variability of Type 2 Diabetes Mellitus Patients with Cardiac Autonomic Neuropathy in Korea (Diabetes Metab J 2017;41:275-83)
por: Kim, Chong Hwa, et al.
Publicado: (2017)

Anti-Inflammatory Effect for Atherosclerosis Progression by Sodium-Glucose Cotransporter 2 (SGLT-2) Inhibitor in a Normoglycemic Rabbit Model
por: Lee, Seul-Gee, et al.
Publicado: (2020)

Body Weight Gain and Hyperphagia After Administration of SGLT-2 Inhibitor: A Case Report
por: Hamamoto, Hiromi, et al.
Publicado: (2015)

Effects on Weight Reduction and Safety of Short-Term Phentermine Administration in Korean Obese People
por: Kim, Kyoung Kon, et al.
Publicado: (2006)

Correction: Dapagliflozin, SGLT2 Inhibitor, Attenuates Renal Ischemia-Reperfusion Injury
por: Chang, Yoon-Kyung, et al.
Publicado: (2016)

Economic Burden of Hypoglycemia in Patients with Type 2 Diabetes Mellitus from Korea
por: Kim, Gyuri, et al.
Publicado: (2016)

The influence of type 2 diabetes mellitus on the expression of inflammatory mediators and tissue inhibitor of metalloproteinases-2 in human chronic periodontitis
por: Kim, Jae-Bung, et al.
Publicado: (2011)

Comparison of SGLT2 inhibitors with DPP-4 inhibitors combined with metformin in patients with acute myocardial infarction and diabetes mellitus
por: Lyu, Young Sang, et al.
Publicado: (2023)

The SGLT-2 Inhibitors in Personalized Therapy of Diabetes Mellitus Patients
por: Tilinca, Mariana Cornelia, et al.
Publicado: (2021)

Longitudinal Changes of High Molecular Weight Adiponectin are Associated with Postpartum Development of Type 2 Diabetes Mellitus in Patients with Gestational Diabetes Mellitus
por: Lee, Dong-Hwa, et al.
Publicado: (2021)

Effectiveness of Exercise Intervention in Reducing Body Weight and Glycosylated Hemoglobin Levels in Patients with Type 2 Diabetes Mellitus in Korea: A Systematic Review and Meta-Analysis
por: Jang, Ji-Eun, et al.
Publicado: (2019)

Cardioprotective mechanism of SGLT2 inhibitor against myocardial infarction is through reduction of autosis
por: Jiang, Kai, et al.
Publicado: (2021)

Renal Effects of SGLT2 Inhibitors and Potential Clinical Implications: Beyond the Heart
por: Lee, Sunki
Publicado: (2022)

Correction: Comparison of SGLT2 inhibitors with DPP4 inhibitors combined with metformin in patients with acute myocardial infarction and diabetes mellitus
por: Lyu, Young Sang, et al.
Publicado: (2023)

Emergence of SGLT2 Inhibitors as Powerful Antioxidants in Human Diseases
por: Tsai, Kai-Fan, et al.
Publicado: (2021)

Canagliflozin: A Novel SGLT2 Inhibitor for Type 2 Diabetes Mellitus
por: Kaushal, Shaveta, et al.
Publicado: (2014)

Pharmacological evaluation of HM41322, a novel SGLT1/2 dual inhibitor, in vitro and in vivo
por: Lee, Kyu Hang, et al.
Publicado: (2019)

Use of SGLT-2 Inhibitors in Patients With Type 1 Diabetes Mellitus
por: El Hage, Lea, et al.
Publicado: (2020)

Can SGLT2 Inhibitor be Used for Diabetes Mellitus or Vascular Diseases?
por: Nomiyama, Takashi
Publicado: (2020)

Comparison of cardiovascular outcomes between SGLT2 inhibitors in diabetes mellitus
por: Suzuki, Yuta, et al.
Publicado: (2022)

Disruption of the Tff1 gene in mice using CRISPR/Cas9 promotes body weight reduction and gastric tumorigenesis
por: Kim, Hyejeong, et al.
Publicado: (2018)

Association of SGLT2 inhibitors with lower incidence of death in type 2 diabetes mellitus and causes of death analysis
por: Chung, Mu-Chi, et al.
Publicado: (2022)

Development and Validation of Prediction Model for Risk Reduction of Metabolic Syndrome by Body Weight Control: A Prospective Population-based Study
por: Lee, Solam, et al.
Publicado: (2020)

The influence of gonadotropin releasing hormone agonist treatment on the body weight and body mass index in girls with idiopathic precocious puberty and early puberty
por: Kim, Sung Woo, et al.
Publicado: (2017)

Class effects of SGLT2 inhibitors on cardiorenal outcomes
por: Kluger, Aaron Y., et al.
Publicado: (2019)

The Association between Helicobacter pylori Infection and Body Weight among Children
por: Choi, Jun Sik, et al.
Publicado: (2016)

Possibility of pharmacokinetic drug interaction between a DPP-4 inhibitor and a SGLT2 inhibitor
por: Gu, Namyi, et al.
Publicado: (2020)

Effect of SGLT-2 inhibitors on body composition in patients with type 2 diabetes mellitus: A meta-analysis of randomized controlled trials
por: Pan, Runzhou, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_9tqm5qgugavhltb96ct5adi3o1